Reminder: Ligand to Host Analyst Day on February 28th in New York City
February 13 2017 - 4:30PM
Business Wire
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will
host an Analyst Day on Tuesday, February 28, 2017 from 10:00 a.m.
to 11:30 a.m. Eastern time (7:00 a.m. to 8:30 a.m. Pacific time) in
New York City at the Andaz 5th Avenue, 485 5th Avenue at East 41st
Street.
Presenters will include:
- John Higgins, Chief Executive
Officer
- Matt Foehr, President and Chief
Operating Officer
- Matt Korenberg, Chief Financial
Officer
- Roland Buelow, Ph.D., Vice President,
Antibody Technologies
- Eric Vajda, Ph.D., Vice President,
Preclinical Research and Development
Presentations will cover the following topics:
- Update on Ligand’s business model and
financials, expanded portfolio, technology platforms and
intellectual property
- Overview of partner and license
portfolio and highlights of Big 6 and Next 12 programs
- Research investment priorities
- Outlook for OmniAb antibody discovery
business and a review of the OMT acquisition one year following the
deal
- Update on Glucagon Receptor Antagonist
(GRA) development program for Type 2 diabetes
- Details of 2017 financial outlook
The event will be webcast live and will be available at
www.ligand.com. A replay of the webcast will be available for 90
days following the event. The presentation will be followed by a
luncheon reception for those attending in person. For more
information or to reserve a seat, please contact Ani Mikaelian at
amikaelian@lhai.com.
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company focused on developing or
acquiring technologies that help pharmaceutical companies discover
and develop medicines. Our business model creates value for
stockholders by providing a diversified portfolio of biotech and
pharmaceutical product revenue streams that are supported by an
efficient and low corporate cost structure. Our goal is to offer
investors an opportunity to participate in the promise of the
biotech industry in a profitable, diversified and lower-risk
business than a typical biotech company. Our business model is
based on doing what we do best: drug discovery, early-stage drug
development, product reformulation and partnering. We partner with
other pharmaceutical companies to leverage what they do best
(late-stage development, regulatory management and
commercialization) to ultimately generate our revenue. Ligand’s
Captisol® platform technology is a patent-protected, chemically
modified cyclodextrin with a structure designed to optimize the
solubility and stability of drugs. OmniAb® is a patent-protected
transgenic animal platform used in the discovery of fully human
mono-and bispecific therapeutic antibodies. Ligand has established
multiple alliances, licenses and other business relationships with
the world's leading pharmaceutical companies including Novartis,
Amgen, Merck, Pfizer, Celgene, Gilead, Janssen, Baxter
International and Eli Lilly.
Follow Ligand on Twitter @Ligand_LGND.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170213006060/en/
Ligand Pharmaceuticals IncorporatedTodd Pettingill, (858)
550-7500investors@ligand.com@Ligand_LGNDorLHABruce Voss, (310)
691-7100bvoss@lhai.com
Ligand Pharmaceuticals (NASDAQ:LGND)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ligand Pharmaceuticals (NASDAQ:LGND)
Historical Stock Chart
From Apr 2023 to Apr 2024